source
- AstraZeneca withdraws EU filing for monoclonal antibody targeting amyloidosis subsetAstraZeneca has announced that it is pulling its European marketing application for a monoclonal antibody intended for a specific subgroup of amyloidosis patients. The decision follows earlier fail…
- Windward Bio launches on Nasdaq after $175 million IPO, secures $50 million from SanofiWindward Bio, a biotech developing drugs for respiratory diseases, completed its initial public offering and began trading on Nasdaq. The offering raised $175 million, with the stock opening at $1…